Given that mice overexpressing wild-type or mutant α-synuclein and mice deficient in cysteine-string protein α (CSPα), a molecular chaperone, both show neurodegenerative changes, the authors tested for possible interactions between these two proteins. Remarkably, they found that increased expression of α-synuclein rescues mice lacking CSPα from degeneration of their presynaptic nerve terminals. Moreover, loss of endogenous synuclein activity accelerated degeneration of presynaptic terminals in mice lacking CSPα. These studies provide compelling evidence that α-synuclein has an activity that complements that of CSPα, a molecular chaperone that is crucial for the integrity of synaptic nerve terminals.
dent, genetic aberrations that increase the copy number of the gene are likely to cause disease due to the increased abundance of α-synuclein available to form inclusions. Mechanisms of sporadic PD where no genetic mutations have been identified may be similar in that a variety of perturbations in normal cellular physiology could lead to abnormal accumulation of α-synuclein, leading to the initiation of neurodegeneration. The way in which the A30P mutation in α-synuclein confers toxicity remains unclear as several studies have shown conflicting results on its effect on polymerization.
Despite these studies, the normal biological function of α-synuclein has remained unclear. Mice deficient in either α-or β-synuclein or lacking both proteins do not have an obvious phenotype (Chandra et al., 2004). Furthermore, although transgenic mice overexpressing wild-type or mutant forms of α-synuclein are useful disease models, they have not been particularly informative as far as revealing the normal functions of this protein. Now, in a surprising series of experiments, Chandra, Südhof, and colleagues (Chandra et al., 2005) demonstrate a dramatic physiological effect of α-synuclein that speaks to the normal function of this protein. Given that mice overexpressing wild-type or mutant α-synuclein and mice deficient in cysteine-string protein α (CSPα), a molecular chaperone, both show neurodegenerative changes, the authors tested for possible interactions between these two proteins. Remarkably, they found that increased expression of α-synuclein rescues mice lacking CSPα from degeneration of their presynaptic nerve terminals. Moreover, loss of endogenous synuclein activity accelerated degeneration of presynaptic terminals in mice lacking CSPα. These studies provide compelling evidence that α-synuclein has an activity that complements that of CSPα, a molecular chaperone that is crucial for the integrity of synaptic nerve terminals.
CSPs are a family of conserved small proteins (167-249 amino acid residues in length) that are abundant in the synapse. They contain a DNA-J domain similar to that of the Hsp40 chaperones, a string of 13 or 14 cysteine residues (hence the name), and a variable carboxy-terminal region (Buchner and Gundersen, 1997). The function of CSP proteins was initially described in the fruit fly Drosophila. Mutant flies typically die during development, although a small percentage survive, and the survivors exhibit temperature-sensitive paralysis, neurodegenerative changes, and a short lifespan. In mice, CSPα is localized to the cytoplasmic face of presynaptic vesicles, accounting for w1% of total vesicle protein. The cysteine-rich region is highly palmitoylated, which enables this protein to be readily targeted to membranes. CSPα has Hsp40-like activity and forms a trimeric complex with Hsc70 and SGT (glutamine-rich tetratricopeptide repeat protein), which catalyzes the ATP-dependent refolding of denatured proteins (Tobaben et al., 2001). Analysis of CSPα-deficient mice suggests that this protein is a presynaptic molecular chaperone that aids in the folding and refolding of synaptic proteins critical for neurotransmitter release, vesicle re- restoring SNARE complexes to their correct levels and suppressing presynaptic degeneration, motor dysfunction, and death of mice lacking CSPα. Interestingly, both wild-type α-synuclein and α-synuclein carrying the A53T mutation show this activity, whereas the A30P mutant form does not. This may reflect the inability of the A30P mutant to interact with lipid membranes.
The results reported by Chandra, Südhof, and colleagues strongly suggest that α-synuclein acts as an auxiliary molecular chaperone complementing the chaperone activity of CSPα in vivo. In this way, α-synuclein helps to preserve the function and integrity of the synapse. Moreover, α-synuclein normally facilitates the function of CSPα as reduction of endogenous levels of α-synuclein accelerates appearance of the CSPα mutant phenotype. However, to compensate for loss of CSPα function, high levels of α-synuclein (w5-to 10-fold above normal) were typically needed (Chandra et al., 2005). It may be that α-synuclein has only a loose association with synaptic vesicles and that high levels are required to increase the concentration of α-synuclein close to the SNARE protein complexes. In addition, α-synuclein may be a less efficient chaperone than CSPα as it is ATP-independent and does not interact with Hsc70 class chaperones; it also may have a lower affinity for the substrates that CSPα unfolds.
These studies highlight a dual role for α-synuclein in neurodegeneration: mutant α-synuclein or the abnormal accumulation of wild-type α-synuclein induces neurodegeneration, whereas the normal functions of α-synuclein help to enhance synaptic activity and integrity. A key question is whether and how these two conflicting roles of α-synuclein are connected. For example, given that mutant α-synuclein plays a key role in the development of PD and other neurodegenerative diseases, it would be interesting to know whether upregulation of β-synuclein-which does not form pathological cellular inclusions-would also be able to rescue the function of CSPα. Does sequestration of α-synuclein in pathological inclusions lead to its depletion at nerve terminals, thereby reducing chaperone activity that is critical for nerve terminal integrity? Does altered CSPα function contribute to PD? Does upregulation of CSPα hold therapeutic promise for treating neurodegenerative diseases as has been suggested for the chaperone Hsp70 (Auluck et al., 2002)? Although these ideas are speculative, the study by Chandra, Südhof, and colleagues provides the first compelling evidence for the physiological activity of normal α-synuclein in vivo. Their findings present a framework for understanding the normal functions of α-synuclein and how aberrant activity of this protein leads to neurodegeneration in PD and other synucleinopathies. Nancy M. Bonini 1 and Benoit I. Giasson
